Could some breast cancer patients avoid surgery? new trial explores the possibility

NCT ID NCT06938724

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The goal is to see if avoiding these local treatments is as safe as standard care for these highly selected patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Omission of surgery or radiotherapy
What this could lead to
If successful, this could show that some women with these breast cancer types can avoid surgery or radiation after a complete response to chemotherapy, reducing treatment burden.
What could go wrong
This is a small, early-phase trial with only 152 participants. It is not yet proven that skipping local therapies is safe, and there is a risk of cancer returning without these treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM MALIGNANT FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Nazionale Tumori Milano

    RECRUITING

    Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.